Scientists at Galileo Pharmaceuticals confirm inflammatory response linked to glucose levels
A team of scientists has discovered three molecules –?from a search of 58,000 compounds –?that appear to inhibit a key perpetrator of Alzheimer's disease. Ken Kosik, co...CM Galactose Broth from Aestus Pharmaceuticals Corp.
Description:...Water, USP Purified/WFI G from Aestus Pharmaceuticals Corp.
Description:US Pharmacopoeia Purified-Water/Water-for-Injection Quality Water...CM Glucose Broth from Aestus Pharmaceuticals Corp.
Description:Growth Medium / Media...Deltanoid Pharmaceuticals begins phase II osteoporosis study
The study is being conducted to determine whether 2MD can safely improve bone mineral density in postmenopausal women. Osteoporosis, a disease caused by the loss of nor...The Coming of Biotech Generic Pharmaceuticals
CHICAGO In a column last year, I commented on the growing generic pharmaceuticals business in the U.S. and around the world. Generic pharmaceuticals are not only big business but will continue to get even bigger. There are a couple reasons why: The increased concern in the U.S. about rising drug pr...Supply of Radiopharmaceuticals Hampered by Attacks
As a result of the September 11 terrorist acts in New York and Washington DC, air transportation in the United States was put on hold for several days, which severely affected the production and distribution of radiopharmaceuticals. Most radiopharmaceuticals are shipped via air due to their specific nature. These products are either radioactive themselves or they are pharmaceuticals wi...FDA approves Watson Pharmaceuticals' Oxytrol patch
The Food and Drug Administration has approved a new patch developed by Watson Pharmaceuticals Inc., for the treatment of an overactive bladder. The patch called Oxytrol (generic: oxybutynin transdermal system) reduces urinary urge incontinence, urinary urgency, and urinary frequency, according to the drug's maker. Oral forms of oxybutynin has been around for around 25 years but it has not been po...Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
Antigenics Pharmaceuticals is to start its Phase III cancer vaccine trial against Melanoma which is a type of skin cancer. Oncophage is the new skin cancer vaccine developed by Antigenics.// The vaccine trial of Oncophage which was conducted in 322 patients failed to meet the required statistically significance results compared to prolongation in survival and the vaccine was not shown to have any...United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
United Kingdom is lagging in innovation, as shown by the market share of new medicines in various countries, including primary care and hospital markets. Reports from various sources prove that Europe has shown very low growth in the field of pharmaceuticals and hospital care//. Europe has a new plan in order to counter the worsening competitive position of its biopharmaceutical enter...BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Jul 11, 2007 - BioSantePharmaceuticals, Inc. (Amex: BPA) today announced new positiveresults demonstrating that its calcium phosphate (CaP)nanoparticle-based vaccine adjuvant, BioVant(TM), may serve as aneffective vaccine adjuvant for the development of a dose sparingvaccine against H5N1 avian flu, widely known as bird flu. The new results are based on...Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
- Results Fail to Demonstrate Meaningful Placebo Adjusted WeightLoss; Obesity Program to be Discontinued NEW YORK, July 09, 2007 /PRNewswire-FirstCall/ -- ManhattanPharmaceuticals, Inc. today announced results of the company's twoPhase 2a clinical trials of oral Oleoyl-estrone (OE). The resultsof both randomized, double-blind, placebo-controlled studies, onein common obesity and the other...Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
MALVERN, Pa., June 28, 2007 /PRNewswire-FirstCall/ -- AuxiliumPharmaceuticals, Inc. today announced that Mr. Armando Anido, ChiefExecutive Officer and President, and Mr. Jim Fickenscher, ChiefFinancial Officer, will participate in the 2007 CEUT EmergingGrowth Opportunities Conference to be held July 10 through July 12,2007 at the Mandarin Oriental Hotel in New York City. Mr. Anido issche...